PMID- 12908938
OWN - NLM
STAT- MEDLINE
DCOM- 20040702
LR  - 20190513
IS  - 0146-4760 (Print)
IS  - 0146-4760 (Linking)
VI  - 27
IP  - 5
DP  - 2003 Jul-Aug
TI  - Comparison and evaluation of DRI methamphetamine, DRI ecstasy, Abuscreen ONLINE 
      amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays 
      for the detection of amphetamine (AMP), methamphetamine (MTH), 
      3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) 
      in human urine.
PG  - 265-9
AB  - The performances of four immunoassays (DRI amphetamines, DRI ecstasy, Abuscreen 
      ONLINE amphetamines, and a modified Abuscreen ONLINE amphetamines) were evaluated 
      for control failure rates, sensitivity, and specificity for amphetamine (AMP), 
      methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 
      3,4-methylenedioxymethamphetamine (MDMA). The two DRI reagents and the ONLINE 
      reagents were run according to manufacturer specifications using a Roche Hitachi 
      Modular DDP system. The modified ONLINE reagent was calibrated with MDMA and had 
      16mM sodium periodate added to the R2 reagent. These assays were run on 
      approximately 27,500 human urine samples and 7000 control urine samples prepared 
      at 350 and 674 ng/mL over the course of 8 days. All assays were calibrated using 
      a single point, qualitative cutoff standard with the manufacturer-recommended 
      compound at the Department of Defense cutoff (500 ng/mL). Gas chromatography-mass 
      spectrometry (GC-MS) confirmation was conducted on screened-positive samples. 
      Control performance for the manufacturer recommended assays was excellent, with a 
      maximum qualitative control failure rate of 2.03%. The modified ONLINE reagent 
      demonstrated poor control performance with a maximum failure rate of 38.3% and 
      showed no improved MDMA sensitivity when compared with the ONLINE reagent; the 
      confirmation rate (20%) was improved when compared with the production ONLINE 
      reagent (8%). The DRI ecstasy reagent provided improved sensitivity for MDMA as 
      compared with the ONLINE reagent, with approximately 23% more samples screening 
      and confirming positive for MDMA and a confirmation rate of approximately 90%. 
      The DRI methamphetamine reagent had a low confirmation rate (6% or less) and 
      produced numerous positives for samples with only ephedrine or pseudoephedrine 
      present.
FAU - Stout, Peter R
AU  - Stout PR
AD  - Aegis Sciences Corp., 345 Hill Avenue, Nashville, Tennessee 37210, USA.
FAU - Klette, Kevin L
AU  - Klette KL
FAU - Wiegand, Russell
AU  - Wiegand R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Anal Toxicol
JT  - Journal of analytical toxicology
JID - 7705085
RN  - 0 (Indicators and Reagents)
RN  - 10450-60-9 (Periodic Acid)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - B45A1BUM4Q (metaperiodate)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/urine
MH  - Amphetamine/*urine
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Immunoassay/methods
MH  - Indicators and Reagents
MH  - Methamphetamine/urine
MH  - N-Methyl-3,4-methylenedioxyamphetamine/analysis/*urine
MH  - Periodic Acid
MH  - Sensitivity and Specificity
MH  - Substance Abuse Detection/*methods
EDAT- 2003/08/12 05:00
MHDA- 2004/07/03 05:00
CRDT- 2003/08/12 05:00
PHST- 2003/08/12 05:00 [pubmed]
PHST- 2004/07/03 05:00 [medline]
PHST- 2003/08/12 05:00 [entrez]
AID - 10.1093/jat/27.5.265 [doi]
PST - ppublish
SO  - J Anal Toxicol. 2003 Jul-Aug;27(5):265-9. doi: 10.1093/jat/27.5.265.